Physician profile
Gary Romaka
NPI 1316280852
$1,585.79
in general payments reported to CMS, 2019-2025
17 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $366 · 2023: $222 · 2024: $429 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026 · Education: $14.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.65 |
| Education | $14.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $356.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $236.08 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $203.22 | 2021-2024 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $191.19 | 2024-2025 | |
| Amgen INC. | $172.58 | 2022-2025 | Tavneos |
| Vifor Pharma, INC. | $135.64 | 2022-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $74.65 | 2021-2024 | Jynarque |
| Glaxosmithkline, LLC. | $59.69 | 2021-2025 | Shingrix, Arexvy |
| Alexion Pharmaceuticals, INC. | $29.31 | 2023 | Ultomiris |
| Calliditas Therapeutics US INC. | $19.35 | 2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $18.92 | 2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $15.72 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $15.33 | 2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $14.91 | 2021 | |
| Opko Pharmaceuticals, LLC | $14.61 | 2024 | Rayaldee |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $14.25 | 2025 | Ibsrela |
| Akebia Therapeutics INC | $13.79 | 2023 | Auryxia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Romaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.